晚期肺癌中药物耐药性路径的表观遗传学调节
Usamah Sayed1, Amina Dawood Suleman2, Shaker Al-Hasnaawei3
1Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
表观遗传机制驱动了对肺癌疗法的耐药性. 未来的治疗方法可以通过精确疗法和生物标志物向表观遗传可塑性来克服这一问题.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 治疗耐药性是晚期肺癌管理的一个主要挑战.
- 表观遗传机制在发展对各种癌症治疗的耐药性方面发挥着至关重要的作用.
研究的目的:
- 审查表观遗传机制如何对化学疗法,向疗法和肺癌免疫疗法的耐药性作出贡献.
- 讨论肺癌表观遗传疗法的挑战和未来方向.
主要方法:
- 关于肺癌耐药性的表观遗传机制的综合文献综述.
- 在治疗耐药性中分析DNA甲基化,基因组修饰和非编码RNA.
主要成果:
- 恶性细胞利用表观遗传可塑性来逃避治疗效果.
- 表观遗传变化促进了基因沉默,激活了生存途径,并改变了瘤微环境.
结论:
- 目前表观遗传疗法的临床应用受到毒性和异质性的限制.
- 下一代表观遗传药物和生物标志物引导的组合为改善肺癌治疗结果提供了希望.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
Treatment Resistant Cancers
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle
